{"groups":[{"description":"Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo HCT\n\nCyclosporine: Given PO\n\nMycophenolate Mofetil: Given PO\n\nSirolimus: Given PO","id":"FG000","title":"Arm I (Mycophenolate Mofetil, Cyclosporine, Sirolimus)"},{"description":"Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo HCT\n\nCyclophosphamide: Given IV\n\nCyclosporine: Given PO\n\nSirolimus: Given PO","id":"FG001","title":"Arm II (Cyclosporine, Sirolimus, Cyclophosphamide)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"75"},{"groupId":"FG001","numSubjects":"75"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"72"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}